TCGA-GM-A2DL-01A-11R-A18M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 117
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- TNFA_SIGNALING_VIA_NFKB+0.490
- ANGIOGENESIS+0.410
- COAGULATION+0.410
- TGF_BETA_SIGNALING+0.410
- MYOGENESIS+0.350
- P53_PATHWAY+0.350
- CHOLESTEROL_HOMEOSTASIS+0.340
- ANDROGEN_RESPONSE+0.310
- KRAS_SIGNALING_UP+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.150
- MYC_TARGETS_V2-0.120
- UNFOLDED_PROTEIN_RESPONSE-0.100
- HEDGEHOG_SIGNALING-0.070
- INTERFERON_ALPHA_RESPONSE-0.070
- PROTEIN_SECRETION-0.070
- KRAS_SIGNALING_DN-0.060
- SPERMATOGENESIS-0.050
- HEME_METABOLISM-0.040
- APICAL_SURFACE-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG893 | — | — | 0.848 |
| 2 | MDT-AP-2040 | Med | Medulloblastoma | 0.842 |
| 3 | TCGA-BH-A0DZ-01A-11R-A00Z-07 | — | C | 0.833 |
| 4 | EPT0508 | EPN | Posterior Fossa EPN | 0.828 |
| 5 | MDT-AP-2149 | Med | Medulloblastoma | 0.823 |
| 6 | TCGA-CN-6020-01A-11R-1686-07 | — | — | 0.819 |
| 7 | SRR10900576 | — | — | 0.819 |
| 8 | MDT-AP-1256 | Med | Medulloblastoma | 0.813 |
| 9 | s_150324_4b | EPN | Posterior Fossa EPN | 0.813 |
| 10 | MDT-AP-0355 | Med | Medulloblastoma | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |